Lianlian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lianlian Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Xiaoyu Zhang
Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, 250062, China
4 shared publicationsYong Wang
Shandong Xinchuang Biotechnology Co., LTD, Jinan, 250102, China
3 shared publicationsHaipeng Yin
Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China
2 shared publicationsHongyan Liu
Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China
2 shared publications- Hongyan Liu
Institute of Basic Medicine,Shandong First Medical University & Shandong Academy of Medical Sciences
2 shared publications Yutao Diao
Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China
2 shared publications
Latest Publications
- 1 May 2019
- Published by Elsevier in Cancer Letters
- Vol. 450, 14-21
HOX cluster-embedded antisense long non-coding RNAs in lung cancer
- 1 May 2019
- Published by Elsevier in Cancer Letters
- Vol. 450, 14-21
HOX cluster-embedded antisense long non-coding RNAs in lung cancer
- 1 December 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 487, 197-201
Long non-coding RNA HOXD-AS1 in cancer
- 1 December 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 487, 197-201
Long non-coding RNA HOXD-AS1 in cancer
- 1 August 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 483, 6-13
Prognostic role of microRNA-155 in patients with leukemia: A meta-analysis
- 1 August 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 483, 6-13
Prognostic role of microRNA-155 in patients with leukemia: A meta-analysis
- Open Access
- 1 August 2017
- Published by Smart Science and Technology, LLC in Cancer Cell & Microenvironment
- Vol. 4 (3)
Roles of alternative splicing in the pathogenesis of lung cancer
Alternative splicing contributes to the vast complexity of mRNA transcripts and protein isoforms. It has been estimated that the majority of protein-coding genes are subject to alternative splicing in humans. Alternative splicing plays a critical role in physiological processes and cell development programs, and dysregulation of alternative splicing is often associated with pathologic conditions such as cancer. Indeed, the abnormal splicing is frequently found in lung cancer, which produces various protein isoforms with properties that may have different functions and therefore even diverse effects on tumor malignant development. In this highlight, we summarize the evidence supporting the functional role of alternative splicing in lung cancer, discuss the regulation of alternative splicing, and highlight the relevance of splicing variation on lung cancer therapy.
- 1 August 2017
- Published by Smart Science and Technology, LLC in Cancer Cell & Microenvironment
- Vol. 4 (3)
Open AccessRoles of alternative splicing in the pathogenesis of lung cancer
Alternative splicing contributes to the vast complexity of mRNA transcripts and protein isoforms. It has been estimated that the majority of protein-coding genes are subject to alternative splicing in humans. Alternative splicing plays a critical role in physiological processes and cell development programs, and dysregulation of alternative splicing is often associated with pathologic conditions such as cancer. Indeed, the abnormal splicing is frequently found in lung cancer, which produces various protein isoforms with properties that may have different functions and therefore even diverse effects on tumor malignant development. In this highlight, we summarize the evidence supporting the functional role of alternative splicing in lung cancer, discuss the regulation of alternative splicing, and highlight the relevance of splicing variation on lung cancer therapy.